News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Develops New Bispecific Antibodies That Exhibit Potent Anti-Lymphoma Activity



12/12/2012 9:10:13 AM

ATLANTA, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that two new classes of bispecific antibodies were created as the DOCK-AND-LOCK™ (DNL™) complexes using the Company's patented platform technology that enables site-specific conjugation of two self-assembling modules. These bispecific antibodies exhibited potent cell killing activity against lymphoma cell lines in vitro.

Read at GlobeNewswire

Related News

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES